Zacks Investment Research downgraded shares of Sientra (NASDAQ:SIEN) from a hold rating to a sell rating in a report released on Friday, Zacks.com reports.
According to Zacks, “Sientra, Inc. is a medical aesthetics company. The Company offers plastic surgery implantable devices for cosmetic and reconstructive surgery, including Breast Implants, Tissue Expanders, Body Contouring, Implants and Specialty Products. Sentra’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures. It also offers a range of other aesthetic and specialty products. Sientra, Inc. is headquartered in Santa Barbara, California. “
SIEN has been the subject of a number of other research reports. Canaccord Genuity set a $13.00 target price on shares of Sientra and gave the company a buy rating in a research report on Tuesday, September 24th. Stephens set a $16.00 target price on shares of Sientra and gave the company a buy rating in a research report on Friday, August 9th. ValuEngine raised shares of Sientra from a hold rating to a buy rating in a research report on Wednesday, October 2nd. Craig Hallum decreased their target price on shares of Sientra from $20.00 to $14.00 and set a buy rating for the company in a research report on Thursday, July 25th. Finally, BidaskClub upgraded Sientra from a sell rating to a hold rating in a report on Thursday. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. Sientra has an average rating of Buy and a consensus target price of $15.75.
Shares of Sientra stock traded up $0.13 on Friday, hitting $6.34. The stock had a trading volume of 401,739 shares, compared to its average volume of 868,869. The firm has a market capitalization of $312.26 million, a P/E ratio of -1.95 and a beta of 0.24. The stock has a 50 day moving average of $6.65 and a 200 day moving average of $6.77. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.99 and a current ratio of 2.33. Sientra has a twelve month low of $4.78 and a twelve month high of $24.29.
Sientra (NASDAQ:SIEN) last released its earnings results on Thursday, August 8th. The medical instruments supplier reported ($1.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.50). The firm had revenue of $20.53 million for the quarter, compared to analyst estimates of $19.04 million. Sientra had a negative net margin of 151.96% and a negative return on equity of 123.80%. The business’s revenue for the quarter was up 17.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.73) EPS. Equities analysts expect that Sientra will post -2.42 earnings per share for the current year.
Large investors have recently modified their holdings of the business. Schroder Investment Management Group purchased a new stake in shares of Sientra during the 2nd quarter valued at $7,700,000. UBS Group AG increased its position in shares of Sientra by 37.9% during the 2nd quarter. UBS Group AG now owns 2,657,863 shares of the medical instruments supplier’s stock valued at $16,372,000 after purchasing an additional 730,475 shares during the last quarter. Vanguard Group Inc. increased its position in shares of Sientra by 64.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,857,953 shares of the medical instruments supplier’s stock valued at $11,445,000 after purchasing an additional 727,906 shares during the last quarter. Marshall Wace LLP increased its position in shares of Sientra by 6,998.6% during the 2nd quarter. Marshall Wace LLP now owns 710,142 shares of the medical instruments supplier’s stock valued at $4,375,000 after purchasing an additional 700,138 shares during the last quarter. Finally, Citadel Advisors LLC increased its position in shares of Sientra by 421.7% during the 2nd quarter. Citadel Advisors LLC now owns 450,910 shares of the medical instruments supplier’s stock valued at $2,778,000 after purchasing an additional 364,473 shares during the last quarter. Institutional investors and hedge funds own 88.91% of the company’s stock.
Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.
Further Reading: Net Income
Get a free copy of the Zacks research report on Sientra (SIEN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.